The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-26 and is reviewed periodically as new material appears.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Knoxville's pre-1850s population consisted primarily of European-American (of mostly English, Scots-Irish, or German descent) Protestants and a small community of free blacks and slaves. Railroad construction in the 1850s brought to the city large numbers of Irish Catholic immigrants, who helped establish the city's first Catholic congregation in 1855. The Swiss were another important group in 19th-century Knoxville, with businessmen James G. Sterchi and Peter Staub, Supreme Court justice Edward Terry Sanford, philosopher Albert Chavannes, and builder David Getaz, all claiming descent from the city's Swiss immigrants. Welsh immigrants brought mining and metallurgical expertise to the city in the late 1860s and 1870s. After the Civil War, African Americans, both freed slaves and blacks that had been free prior to the war, played an increasing role in the city's political and economic affairs. Racetrack and saloon owner Cal Johnson, born a slave, was one of the wealthiest African Americans in the state by the time of his death. Attorney William F. Yardley, a member of the city's free black community, was Tennessee's first black gubernatorial candidate in 1876. Knoxville College was founded in 1875 to provide educational opportunities for the city's black community. Greek immigrants began arriving in Knoxville in significant numbers in the early 20th century.
In the U.S., the Federal Food, Drug, and Cosmetic Act groups skin care products into two main categories: cosmetics and drugs. While prescription drugs must go through a strict approval process before they can be sold, cosmetics do not need FDA approval before being sold, although they are still monitored for labeling, safety, and are regulated. Cosmeceutical and nutricosmetic are marketing terms with no scientific evidence pertaining to skin care or health, and no acceptance for validity as skin care products under US law.
Panago (originally Panagopoulos) is a privately owned quick service pizza chain with 174 franchised locations in Canada, 151 of which are in British Columbia and Alberta. It is headquartered in Abbotsford, British Columbia, where in 1986 the first three stores opened. In recent years it has attempted to make its food healthier as provincial healthier eating guidelines became more strict. Offerings include multigrain crusts, salads, 33 pizza toppings, and other menu items that have no trans fat, MSG, artificial flavours or artificial colours.
Belize is a country on the north-eastern coast of Central America. It is bordered by Mexico to the north, the Caribbean Sea to the east, and Guatemala to the west and south. It also shares a maritime boundary with Honduras to the southeast. Part of the Caribbean region, Belize is a member of the Caribbean Community (CARICOM) and the Commonwealth Caribbean, the historical British West Indies. The Maya civilization spread into the area of Belize between 1500 BC and 300 AD and flourished until about 1200. European contact began in 1502–1504 when Christopher Columbus sailed along the Gulf of Honduras. European exploration was begun by English settlers in 1638. Spain and Britain both laid claim to the land until the British victory over the Spanish in the Battle of St. George's Caye (1798). It became a British colony in 1840 and a Crown colony in 1862. From then until 1973 it was known as British Honduras. Belize achieved its independence from the United Kingdom on 21 September 1981. It is the only mainland Central American country which is a Commonwealth realm, with King Charles III as its monarch and head of state, represented by a governor-general. Belize's abundance of terrestrial and marine plants and animals and its diversity of ecosystems, including extensive coral reefs, give it a key place in the globally significant Mesoamerican Biological Corridor. It is considered a part of both Central America and the Caribbean. It has an area of 22,970 square kilometres (8,867 sq mi) and a population of 397,483 (2022).
Wrist braces (splints) alleviate symptoms by keeping the wrist straight, which avoids the increased pressure in the carpal tunnel associated with wrist flexion or extension. They are used primarily to help people sleep. Many health professionals suggest that for the best results, one should wear braces at night. When possible, braces can be worn during the activity, primarily causing stress on the wrists. The brace should not generally be used during the day as wrist activity is needed to keep the wrist from becoming stiff and to prevent muscles from weakening.
Sources: en.wikipedia.org
== External links == IFR/JIC TOF MS Tutorial Jordan TOF Products TOF Mass Spectrometer Tutorial University of Bristol TOF-MS Tutorial Kore Technology – Introduction to Time-of-Flight Mass Spectrometry
== Medical uses == Metribolone was never approved for medical use, a situation unlikely to change given its liver toxicity even at low doses. It was studied for the potential treatment of advanced breast cancer in women but development was abandoned.
== Notes == An α indicates the medicine is on the complementary list for which specialized diagnostic or monitoring or training is needed. An item may also be listed as complementary on the basis of higher costs or a less attractive cost-benefit ratio.
Size-exclusion chromatography (SEC) is also known as gel permeation chromatography (GPC) or gel filtration chromatography and separates molecules according to their size (or more accurately according to their hydrodynamic diameter or hydrodynamic volume). Smaller molecules are able to enter the pores of the media and, therefore, molecules are trapped and removed from the flow of the mobile phase. The average residence time in the pores depends upon the effective size of the analyte molecules. However, molecules that are larger than the average pore size of the packing are excluded and thus suffer essentially no retention; such species are the first to be eluted. It is generally a low-resolution chromatography technique and thus it is often reserved for the final, "polishing" step of a purification. It is also useful for determining the tertiary structure and quaternary structure of purified proteins, especially since it can be carried out under native solution conditions.
=== Magnetic and Magnetoelectric nanoparticles === In contrast to the above mechanisms, a delivery with magnetic fields does not strongly depend on the biochemistry of the brain. In this case, nanoparticles are literally pulled across the BBB via application of a magnetic field gradient. The nanoparticles can be pulled in as well as removed from the brain merely by controlling the direction of the gradient. For the approach to work, the nanoparticles must have a non-zero magnetic moment and have a diameter of less than 50 nm. Both magnetic and magnetoelectric nanoparticles (MENs) satisfy the requirements. However, it is only the MENs which display a non-zero magnetoelectric (ME) effect. Due to the ME effect, MENs can provide a direct access to local intrinsic electric fields at the nanoscale to enable a two-way communication with the neural network at the single-neuron level. MENs, proposed by the research group of Professor Sakhrat Khizroev at Florida International University (FIU), have been used for targeted drug delivery and externally controlled release across the BBB to treat HIV and brain tumors, as well as to wirelessly stimulate neurons deep in the brain for treatment of neurodegenerative diseases such as Parkinson's Disease and others.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.